Chemical industry – Page 73
-
Business
Dow to shed up to 1750 jobs by 2017
Chemical giant will lay off about 3% of its global workforce in the next two years
-
BusinessMerger creates biggest supplier of unlicensed drugs
Clinigen will buy Idis to consolidate different routes by which doctors can access medicines that are unavailable locally
-
BusinessGenerics firms in three-way takeover battle
Mylan is chasing Perrigo, while fending off advances from Teva
-
OpinionFlexible, faster formulation
The chemical using industries remain central to UK economic recovery, explains Simon Rushworth
-
Business
Daiichi Sankyo steps out after Sun-Ranbaxy merger
Ranbaxy’s Japanese owner has sold off its stake in the merged company, but will retain its business partnership
-
Business
Generics giant Mylan offers $30 billion for Perrigo
Mylan makes ambitious takeover offer just weeks after Abbott aquisition closes
-
Business
BMS invests in gene therapy
Bristol-Myers Squibb makes $100 million deal with biotech uniQure
-
Business
Leak causes explosion at para-xylene plant in China
Twelve injured by explosion and fire caused by a leaking xylene tank at chemical plant
-
Business
Novartis accused of ‘derailing’ trials for cheap eye disease drug
BMJ says pharma giant is trying to block access to a drug that would save the NHS millions
-
Business
Horizon to acquire orphan drugs in $1.1bn Hyperion takeover
Horizon will buy Hyperion and add new drugs to its rare disease portfolio
-
BusinessEnvironmental research goes private
Exclusive interview with Fera chief Hilary Aldridge as the UK’s Food and Environment Research Agency becomes majority-owned by Capita
-
Business
Dow sells off chlorine assets in $5bn deal
US chemical giant disposes of unwanted operations in tax-free deal
-
Business
Sun Pharma snares Ranbaxy in $4bn deal
Acquisition makes Sun biggest drug firm in India and fifth largest generics producer in the world
-
Business
Teva buys Auspex Pharmaceuticals for $3.2bn
Generics giant will add late stage Huntingdon’s drug to CNS portfolio
-
Opinion'What gets measured gets done'
Measuring R&D productivity is a thorny issue. Dennis Lendrem urges the pharmaceutical industry to learn from its mistakes.
-
Business
Valeant heads off Endo bid for Salix
Bid raised to $15.8 billion in cash after rival offer from Irish firm
-
OpinionAnalogues by catalogue
Buying in screening compounds directly feels like cutting out the synthetic chemist middleman, says Derek Lowe
-
Business23andMe jumps into drug R&D
Gene profiling firm aims to capitalise on its databank of genetic information to discover new drugs